The ARRIVE Web site is designed to help researchers and clinicians understand the importance and value of the ARRIVE Trial, one of the largest clinical studies ever conducted in a population at moderate risk of initial CVD events. The ARRIVE trial and this Web site exemplify Bayer’s commitment to work with the scientific community to continue exploration of Aspirin as a cornerstone of CVD event prevention.
The ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) trial is one of the largest clinical studies ever conducted in a population at moderate risk of initial events associated with cardiovascular and cerebrovascular disease (CVD). ARRIVE will expand the already existing, strong body of evidence supporting use of Aspirin for primary prevention of events associated with CVD. Learn more
Aspirin is not appropriate for everyone, so consumers are directed to speak with their physicians before beginning an Aspirin regimen.
Do you know someone who may be interested in the ARRIVE trial
Send them an email